EBD Group: Carola Schropp. It's all about the team!




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: EBD Group: Carola Schropp. It's all about the team!
Released on: February 06, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, filmed at BioEurope 2012 in Hamburg, Germany, Fintan Walton talks to Carola Schropp, President of the EBD Group
Success component of BioEurope
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at BioEurope, in Hamburg, in 2012. On this show I have the President of the EBD Group, which runs this event, Carola Schropp, welcome.
Carola Schropp:
Thank you very much for having me.
Fintan Walton:
Carola, you are coming up to nearly 20-years of running BioEurope, of course you run other conferences as well, what makes BioEurope such a success?
Carola Schropp:
There is one answer, it's the team. We have an outstanding team that has been together for a long, long time. We are now over 50 people, 55 I believe, and we've only ever lost one person that has stayed with us for you know for a year, of course you have some people that turns out after a couple of months that it doesn't work out, but if you look at the others that have stayed past a year we have lost one person, I mean if I think about it this is incredible.
Fintan Walton:
It is incredible and I think people can see how the benefit of that has been for those who attend the conference. So the team, you draw a team together for each of these events and of course these are international events, here we are in Germany today but you run these events around the world, for you and making sure that the team works, what's the other important ingredient for you?
Carola Schropp:
It's comes back to the team, I could talk about the technology, we have great technology, developed by the team of course, but in the end what can I say it's this it's that they have known each other for so long, they know how things work, they know each other as people and they are really focused on servicing the community. I mean when I go around here I get all these compliments from all these people who say this is a unique approach, and I am thinking it shouldn't be so unique, it's not rocket science, put yourself in the position of the attendee that's our mantra, that's our goal.
Fintan Walton:
Yes, of course.
Carola Schropp:
And before we did this, I mean I've been to so many conferences and I know what I liked and what I didn't like and so I just we always put ourselves in the position of the attendee.
Fintan Walton:
Right, and of course, the other thing of course they are motivated, I think your team is a motivated team.
Carola Schropp:
They are having fun, having great fun. They have parties here at the event, it's going to be a staff party tonight, it's going to not end today but probably very late tomorrow.
Fintan Walton:
Fantastic.
Carola Schropp:
So people know each other as friends and there is no positioning yourself, it will be a very flat organization, you can't get anywhere by trying to impress me, it won't work.
Partnering at events
Fintan Walton:
Sure, okay. Carola, the other component of course to all of this all of these events are partnering events, so what are your thoughts about partnering, because obviously you are observing the partnering going on at these events over the years, what is it?
Carola Schropp:
I am still amazed, at this meeting there is going to be or they have been close to 16,000 meetings, this boggles my mind, and I have been thinking a lot about why, because you talk to people and they say yes of course you have to meet some people again then other people from your companies meet other people, what is it and I believe that in these meetings there is much more going on than just the follow-up from where you used to be. I think and whenever you talk to somebody about complementary issues that you come up with new ideas, just you by yourself you talk about something you come up with ideas and so does the other person, and so you go from being like this to being like this, you are team players. We are tribal people, you know if you look back at the evolution, and we love to be doing things together, that's in us.
Fintan Walton:
Yes, so it's back to the team idea really it's how we interact as human beings and how ideas are generated and those ideas of course ultimately lead to deals?
Carola Schropp:
Yes.
Fintan Walton:
Does technology make deals or do people make deals?
Carola Schropp:
People of course make deals, and you know 30-years of technology will not out do 30,000 years of evolution, people have to see each other, whether it's chemistry or physics that attract us it makes such a difference, just even on a phone call, you sit there picture a person if you don't know them, you have to see each other, it's human nature.
Carola Schropp's perspective: Future growth of Biotech industry
Fintan Walton:
The other thing I am always amazed by is that the numbers keep going up, the number of attendees going up, now we've, we were all going through tough times and the laws of physics say you should be, your numbers should be dropping down, but your actual numbers are going up all the time?
Carola Schropp:
They are going up, I think partnering is very necessary these days.
Fintan Walton:
So obviously over 20-years there are some new people coming, do you see the same faces over the last 20-years?
Carola Schropp:
Yes. We have an incredibly high retention rate, it's amazing, in this industry people switch jobs, but they still come, so the challenge is of course getting the database all sorted out, but it's lovely, it feels like such a community and that's what people appreciate here.
Fintan Walton:
And of course, I mean from your perspective, because you've seen it again over the last 20-years, is can we ask the question is biotech on the way up or is it on the way down?
Carola Schropp:
I think biotech is on the way up, because ultimately we want to cure disease and in my opinion we have regenerative medicine, it's a great way to get to the goal, it's not the only one, but we will continue to work on this, and look at, I mean it's taken a long time in oncology for instance, when Nixon said in 1973 we are going to Nix this cancer game within 10-years, well 40-years later still not quite done yet, but we are seeing the light at the end of this tunnel.
Fintan Walton:
Right.
Carola Schropp:
So because of that biotech will continue.
Fintan Walton:
Carola Schropp, thank you very much indeed for coming on the show.
Carola Schropp:
You're very welcome Fintan.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Carola Schropp
Founder and President
At the time of recording this PTV interview Carola Schropp serves as serves as Founder and President at EBD Group. Carola Schroppp is Founder and President of EBD Group and widely recognized as one of the original proponents of our global and interconnected bio-economy. Over the past 15 years, Carola has built EBD Group into the leading partnering firm in the life science market. Under her leadership, EBD Group has grown into an organization that today spans five international partnering events on three continents that generate over 30,000 one-to-one meetings annually, and features partnering services for dozens of other events worldwide. In addition to managing the day-to-day operations of the firm, Carola is focused on bringing EBD Group partnering events to new international markets, and developing new services and technologies that foster more collaboration and growth of the biotech industry. She holds a Masters degree in Business Administration (MBA) and an MTS degree, both from Emory University, Atlanta, GA.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since its inception in 1993, EBD Group's mission has been to facilitate the biotech-pharma partnerships that deliver tomorrow's healthcare treatments to patients worldwide. Biotech, pharma and medical device companies actively leverage EBD Group's partnering conferences, technology and services to identify new business opportunities and develop the strategic relationships essential to their future success. EBD Group produces seven of its own landmark partnering events, and provides partnering services for dozens of other industry events. These conferences all feature partneringONE, EBD Group's powerful networking software that takes partnering productivity to a higher level. Executives from across the biotechnology value chain today rely on partneringONE" to efficiently identify new opportunities and start the deal making process through focused one-to-one meetings. By generating over 30,000 such partnering meetings annually, partneringONE" has become an important catalyst for the growth of the bio-economy. Building on this expertise and with unrivaled access to major players in the life science market, EBD Group's consultants provide expert hands-on assistance for firms seeking to in- or out-license products and technologies and develop results-oriented partnering strategies.